Metabomed is a drug-discovery company in the field of cancer metabolism, with a proprietary target-identification platform based on computational biology and metabolomics.

The company focuses on developing drugs that inhibit targets that form a synthetic lethal gene pair with metabolic genes inactivated in cancer cells.Using this target-inhibiting strategy, Metabomed intends to develop more selective, highly focused anticancer drugs with the ability to kill cancer cells without harming normal cells.